Author:
Schmitt-Koopmann Caroline,Baud Carole-Anne,Beuriot Stéphanie,Junod Valérie,Broers Barbara,Simon Olivier
Abstract
BACKGROUND AND AIM: In Switzerland, a cantonal authorisation is required to introduce opioid agonist treatments (OAT). We investigated and compared the terms of these cantonal OAT authorisations throughout Switzerland. The primary objective was to determine how the overseeing cantonal officials implemented and perceived the legal requirements.
METHOD: We started with a cross-sectional analysis of legal texts and cantonal OAT guidelines. Based on the document analysis, we conducted 26 semi-structured interviews with the cantonal officials who grant OAT authorisations.
FINDINGS: In most cantons (21 of 25), the OAT authorisation is specific to the person treated and must be renewed every year. Today, 21 cantons either have implemented or are implementing the same web-based software to process and manage OAT authorisation requests. Cantons have implemented diverging requirements regarding, amongst others, the involvement of third parties in OAT and the training required of prescribing physicians. Lastly, the OAT process does not seem to be a high priority for the overseeing officials.
CONCLUSIONS: From a legal standpoint, OAT authorisations should be straightforward, yet we found significant divergences among cantonal systems. We could not find scientific evidence that supports a given framework. We recommend harmonizing the 26 cantonal systems while reviewing the need for OAT authorisation.
Publisher
SMW Supporting Association
Reference39 articles.
1. Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019 Jan;114(1):103–11. 10.1111/add.14442
2. Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Sep;78(9):979–93. 10.1001/jamapsychiatry.2021.0976
3. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug;10(11):1727–40. 10.1517/14656560903037168
4. Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020 Jan;6(1):3. 10.1038/s41572-019-0137-5
5. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence [Internet]. Geneva: World Health Organization; 2009 [cited 2021 Aug 23]. Available from: https://apps.who.int/iris/handle/10665/43948